Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
$7.10-6.95%
报价 2026-11-16
市值
$293.6M
EV
$260.9M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -77.5%
$5.10$31.57
筛选结果
pipeline · 2026-11-16Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-11不在筛选范围:industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| EVMNFunctional Brands, Inc. Common Stock | $293.6M | -6.9% | -96.2% | 100% | – | – | – | |
| LGNDLigand Pharmaceuticals, Inc. | $6.04B | -2.3% | +10.6% | 97.5% | 31.8x | 21.8x | 66.6x | |
| FTREFortrea Holdings Inc. | $1.87B | -2.0% | -1.9% | 17.1% | – | 34.8x | 12.5x | |
| ZYMEZymeworks Inc. | $1.84B | +0.8% | – | 98.4% | – | – | – | |
| OABIOmniAb, Inc. | $713.3M | -0.4% | +91.2% | 63.6% | – | – | 312.2x | |
| CLYMClimb Bio, Inc. | $583.9M | -4.1% | – | 0% | – | – | – | |
| ARTVArtiva Biotherapeutics, Inc. | $195.8M | -1.2% | -100.0% | 0% | – | – | – | |
| CDXSCodexis, Inc. | $116.2M | -8.6% | +10.1% | 79.5% | – | – | – | |
| EYPTEyePoint Pharmaceuticals, Inc. | $25.8M | +0.5% | -95.0% | 41.8% | – | – | – | |
| 同行中位数 | – | – | +4.1% | 52.7% | 31.8x | 28.3x | 66.6x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。